glioblastoma
Conditions
Interventions
exprimental group:Oral TMZ 150mg/(m^2.d), d1-7, d15-21, repeat treatment course every 28 days, 8 treatment courses included total.
Control group:Concurrent chemoradio therapy: radiotherapy is synchronized with oral TMZ 75mg/(m^2.d) for 6 weeks
Then 6 courses of TMZ adjuvant chemotherapy: the initial dose of TMZ is 150mg/(m^2.d), d1-5, the first course is 28d
if patient is well tolerated, the second course increased to TMZ 200mg/(m^2.d), d1-5, a course
Sponsors
3rd Affiliated Hospital of Sun Yat-sen University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. diagnosed as WHO IV glioblastoma by histopathology after operation; 2. Aged 18 years to 75 years; 3. Karnofsky Performance Score >=60; 4. Anticipating survival >=2 months; 5. The patients have no dysfunction of major organs, with normal liver and kidney functions were normal. The specific test indexes required: white blood cell>1.5x10^9/L, platelet>100x10^9/L, hemoglobin>10g/dl, and the serum bilirubin was 1.5 times lower than the maximum normal value.ALT and AST were less than 2 times of the maximum normal value. Serum creatinine <=1.5mg/dl.
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating patients 2. Patiens with purulent and chronic infected wounds 3. Patients with liver, kidney and heart insufficiency 4. Uncontrolled psychotic disorders or epilepsy 5. Patients are not suitable to participate the study consider by investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| overall survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| progression-free survival;quality of life; | — |
Countries
China
Contacts
Public ContactChaofeng Liang
3rd Affiliated Hospital of Sun Yat-sen University
Outcome results
None listed